Asthma management in children requires a delicate balance of efficacy and safety, often favoring oral medications over complex inhaler devices that may be difficult for young patients to use correctly. Pranlukast has demonstrated high utility in this demographic, particularly in its dry syrup and granule formulations. These easy-to-administer versions allow for precise weight-based dosing and better patient adherence, which is critical for preventing the long-term structural changes in the lungs that can occur when childhood asthma is poorly controlled.

The Pranlukast Market is witnessing significant traction in the pediatric care sector due to the rising incidence of childhood allergies and environmental sensitivities. Market leaders are focusing on improving the palatability and stability of pediatric formulations to meet the needs of parents and caregivers. With increasing urbanization and pollution levels contributing to early-onset respiratory issues, the demand for pediatric-friendly leukotriene inhibitors is expected to remain a primary engine of growth for the global pharmaceutical industry.